Early rasburicase treatment cuts dialysis, death risk by one-third in tumor lysis syndrome

For more than two decades, oncologists have administered rasburicase to patients in the grip of tumor lysis syndrome — a sudden, life-threatening cascade in which disintegrating cancer cells overwhelm the kidneys — trusting the drug's ability to clear uric acid even without proof it changed survival. Now, a study of 1,276 patients across 36 American hospitals has supplied that proof: treatment within twelve hours reduces the risk of dialysis or death by roughly one-third. It is a quiet but consequential confirmation that in medicine, as in so much of human experience, timing is not incidental